Autolus Therapeutics (AUTL) EBT Margin (2017 - 2026)
Autolus Therapeutics' (AUTL) quarterly EBT Margin came in at 376.78% in Q4 2025, up 8977495.0% YoY from N/an in Q4 2024, and down 1.61% on a QoQ basis from 370.79% in Q3 2025.
Autolus Therapeutics (AUTL) EBT Margin (2017 - 2026) Analysis & Trends
Autolus Therapeutics (AUTL) has 9 years of EBT Margin data on file, last reported at 376.78% in Q4 2025.
- Quarterly EBT Margin rose 8977495.0% year-over-year to 376.78% in Q4 2025, while the trailing twelve-month figure through Dec 2025 was 378.78% (up 178466.0% YoY) and the FY2025 annual result came in at 378.78%, up 178657.0% from the prior year.
- EBT Margin eased to 376.78% in Q4 2025, from 370.79% in the prior quarter.
- In the past five years, EBT Margin ranged from a high of 203.03% in Q4 2022 to a low of 90151.72% in Q4 2024.
- A 5-year average of 11781.28% and a median of 2214.29% in 2022 frame the typical range for EBT Margin.
- Annual changes were most pronounced in 2023 — EBT Margin sank 949254 bps — and 2025, when it soared 8977495 bps.
- Tracing AUTL's EBT Margin over 5 years: stood at 16684.75% in 2021, then surged by 99 bps to 203.03% in 2022, then tumbled by 5465 bps to 11298.03% in 2023, then slumped by 698 bps to 90151.72% in 2024, then soared by 100 bps to 376.78% in 2025.
- The last three EBT Margin figures came in at 376.78% (Q4 2025), 370.79% (Q3 2025), and 227.12% (Q2 2025), per Business Quant data.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | EBT Margin (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 128.13 Bn | 120.28 Bn | 2.84 Bn | 41.75% |
| 2 | Regeneron Pharmaceuticals | 112.33 Bn | 104.33 Bn | 3.93 Bn | 35.61% |
| 3 | Argenx Se | 53.24 Bn | 48.05 Bn | 1.41 Bn | 34.77% |
| 4 | Revolution Medicines | 43.64 Bn | 43.64 Bn | - | - |
| 5 | BeOne Medicines | 39.27 Bn | 34.17 Bn | 1.53 Bn | 18.33% |
| 6 | MindWalk Holdings | 35.32 Bn | 35.31 Bn | 1.82 Bn | -94.22% |
| 7 | Royalty Pharma | 33.72 Bn | 35.84 Bn | - | 12.09% |
| 8 | Alnylam Pharmaceuticals | 30.58 Bn | 27.27 Bn | 992.69 Mn | 13.77% |
| 9 | Insmed | 27.01 Bn | 25.85 Bn | 358.27 Mn | -2.67% |
| 10 | Autolus Therapeutics | 763.37 Mn | 561.74 Mn | 25.22 Mn | -84.58% |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | -84.58% |
| Dec 31, 2025 | -376.78% |
| Sep 30, 2025 | -370.79% |
| Jun 30, 2025 | -227.12% |
| Mar 31, 2025 | -756.36% |
| Dec 31, 2024 | -90,151.72% |
| Mar 31, 2024 | -521.76% |
| Sep 30, 2023 | -11,298.03% |
| Mar 31, 2023 | -3,082.43% |
| Dec 31, 2022 | -203.03% |
| Sep 30, 2022 | -1,805.49% |
| Mar 31, 2022 | -22,342.17% |
| Sep 30, 2021 | -16,684.75% |
| Jun 30, 2021 | -2,623.09% |
| Mar 31, 2021 | -14,494.42% |
| Dec 31, 2020 | -11,990.59% |
| Sep 30, 2020 | -10,315.07% |
| Jun 30, 2020 | -13,333.11% |
| Mar 31, 2020 | -9,931.66% |
| Jun 30, 2019 | -2,708.56% |